Results 101 to 110 of about 3,796 (149)

LHRH Receptor Targeted Therapy for Breast Cancer

2008
Breast cancer remains the most common cancer among women, with an estimated 212,920 new cases and 40,970 deaths in the United States in 2006. The present work extends the studies of nanoparticles targeted to the luteinizing hormone-releasing hormone (LHRH) receptor which is overexpressed in breast, ovarian, endometrial and prostate cancer cells.
S S, Kakar, H, Jin, B, Hong, J W, Eaton, Kyung A, Kang   +4 more
openaire   +2 more sources

Modulation of hippocampal LHRH receptors by sex steroids in the rat

Peptides, 1988
The modulation of brain LHRH receptors by sex steroids was assessed in the female rat hippocampus using in vitro autoradiography and iodinated [D-Ser (TBU)6, des-Gly-NH2(10)]LHRH ethylamide as the radioligand. As evaluated by optical densitometry, the density of hippocampal LHRH receptors was increased by castration.
Badr M, MARCHETTI, Bianca Maria, Pelletier G.   +2 more
openaire   +3 more sources

LHRH receptor expression in sarcomas of bone and soft tissue

Hormone Molecular Biology and Clinical Investigation, 2016
Abstract Aim: Luteinizing hormone releasing hormone (LHRH) is a neurohormone, secreted by the hypothalamus, which regulates the secretion of gonadotropins, luteinizing hormone (LH) and follicle stimulating hormone (FSH) from the pituitary.
Chenthuran, Deivaraju, H Thomas, Temple, Norman, Block, Philip, Robinson, Andrew V, Schally   +4 more
openaire   +2 more sources

Targeting of Peptide Cytotoxins to LHRH Receptors For Treatment of Cancer

Current Drug Targets, 2016
Receptors for LHRH (luteinizing hormone-releasing hormone) are expressed in about 80% of human endometrial, ovarian and prostate cancers and are also found in more than 50% of breast cancers including triple negative breast cancers. In the human body, LHRH receptors are found at significant levels in the pituitary and reproductive organs.
Jorg B, Engel, Hans-Rudolf, Tinneberg, Ferenc G, Rick, Enniko, Berkes, Andrew V, Schally   +4 more
openaire   +2 more sources

Receptor-mediated internalization of LHRH antagonists by pituitary cells

Molecular and Cellular Endocrinology, 1983
A fluorescently labeled antagonist of luteinizing hormone releasing hormone (LHRH), D-pGlu-D-Phe-D-Trp-Ser-Tyr-D-Lys6-(tetramethylrhodamine)-Leu-Arg-Pro-Gly-NH2, was prepared. This peptide retained high-affinity binding to the LHRH receptor of pituitary plasma membrane preparations.
E, Hazum, R, Meidan, M, Liscovitch, D, Keinan, H R, Lindner, Y, Koch   +5 more
openaire   +2 more sources

Effects of an LHRH agonist and gonadotropins on testicular prolactin receptors

Peptides, 1982
Effects of administration of the LHRH agonist D-Leu6-LHRH ethylamide (LHRH-A), gonadotropin (PMS), and their interaction on testicular prolactin (PRL) receptor levels were investigated in rats. LHRH-A (2 micrograms/100 g body wt.) or saline was injected SC daily, and PMS (5 IU) injected every other day.
J B, Fishback, A, Arimura, C M, Turkelson   +2 more
openaire   +2 more sources

Opposite Changes of Pituitary and Ovarian Receptors for LHRH in Ageing Rats: Further Evidence for a Direct Neural Control of Ovarian LHRH Receptor Activity

Neuroendocrinology, 2008
Hypophyseal and ovarian receptors for the neurohormone LHRH (LHRH-R) have been measured in young (3–4 months), middle-aged (8–11 months), constant estrous (CE, 10–14 months) and pseudopregnant (PR, 16–18 months) rats in order to study whether changes in hypothalamic and/or peripheral LHRH-like peptide production might precede and/or accompany the onset
MARCHETTI, Bianca Maria, CIONI, Matteo
openaire   +3 more sources

Abstract 5476: LHRH receptor targeting as mechanism of anti-tumor activity for cytotoxic conjugates of Disorazol Z with the LHRH receptor agonistic peptide D-Lys6-LHRH.

Cancer Research, 2013
Abstract Background For drug-targeting aimed at the treatment of LHRH receptor overexpressing cancers the LHRH receptor agonistic peptide D-Lys6-LHRH has been conjugated to the novel highly cytotoxic natural compound Disorazol Z.
Babette Aicher, Tilmann Schuster, Lars Blumenstein, Antje Schubert, Carsten Gründker, Joerg B. Engel, Olaf Ortmann, Rolf Mueller, Eckhard Guenther, Matthias Gerlach, Michael Teifel   +10 more
openaire   +1 more source

The prolonged action of the LHRH agonist buserelin (HOE 766) may be due to prolonged binding to the LHRH receptor

Life Sciences, 1986
Hemi-pituitary glands of ovariectomized rats were superfused for 4 h with either LHRH or the analog buserelin (HOE 766) at several concentrations, and thereafter with medium only for another 1.5 h. In a further experiment glands were exposed for 2.5 h to LHRH or buserelin at a single concentration (5 ng/ml) and subsequently for another 2.5 h to either ...
Koiter, T. R., Denef, C., Andries, M., Moes, H., Schuiling, G. A.   +4 more
openaire   +3 more sources

Solubilization of a large molecular weight form of the rat LHRH receptor

Journal of Endocrinology, 1987
ABSTRACT The LHRH receptor has been solubilized from male rat anterior pituitary glands, using the zwitterionic detergent 3-((3-cholamidopropyl)-dimethylammonio)-1-propanesulphonate in the presence of a high concentration of sodium chloride. This method gave high yields (up to > 70%) of the LHRH-binding site from the membrane preparation ...
S A, Ogier, R, Mitchell, G, Fink
openaire   +2 more sources